Abstracts tagged "gout"

Abstract Number: 0550 • ACR Convergence 2022
Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…
Abstract Number: 1788 • ACR Convergence 2022
Pulmonary Vascular Dysfunction Occurs in Association with Hyperuricaemia: Assessment by a Novel Non-Invasive Measurement of Pulmonary Pulse Wave Transit Time
Rachael Flood¹, Nicole Fagan², Diarmuid O'Brien¹, Colm Kirby¹, David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²St James' Hospital, Dublin, Ireland
Background/Purpose: Hyperuricaemia is common in pulmonary hypertension (PH) occurring in up to 80% of patients with serum uric acid levels(sUA) correlating with poor PH outcomes.…
Abstract Number: 1807 • ACR Convergence 2022
Reduction in Monosodium Urate Crystal Deposit Volume During the MIRROR RCT Trial in Patients Treated with Pegloticase Plus Methotrexate Co-therapy: A Serial Dual-Energy Computed Tomography (DECT) Analysis
Nicola Dalbeth¹, John Botson², kenneth saag³, Ada Kumar⁴, Lissa Padnick-Silver⁵, Brian LaMoreaux⁵ and Fabio Becce⁶, ¹University of Auckland, Auckland, New Zealand, ²Orthopedic Physicians Alaska, Anchorage, AK, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Horizon Therapeutics, Deerfield, IL, ⁵Horizon Therapeutics plc, Deerfield, IL, ⁶Lausanne University Hospital (CHUV), Lausanne, Switzerland
Background/Purpose: Dual-energy computed tomography (DECT) can reliably visualize and quantify monosodium urate (MSU) crystal deposits in gout patients.1 Two MIRROR open-label trial (pegloticase + oral…
Abstract Number: 1827 • ACR Convergence 2022
The Updated Cardiovascular Risk Tool SCORE2 Provides No Advantage in Identifying Patients with Gout and Carotid Atheroma Plaques
Ernesto Tovar-Sugrañes, Maria-Carmen Lopez-Gonzalez, Cristina Rodriguez-Alvear, Elisabet Perea-Martinez and Mariano Andrès, Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain
Background/Purpose: Standard cardiovascular (CV) risk assessment tool (SCORE, Framingham Heart Study) performed inaccurately in patients with gout and carotid atheroma plaques (thus, at high CV…
Abstract Number: 1006 • ACR Convergence 2022
Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielmann², Corine Gaillez³, Weibin Bao⁴, Hugh O’Neill⁵, jacques-eric gottenberg⁶, Pierre-Marie Duret² and Laurent Messer⁷, ¹Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Colmar Civilian Hospitals, Colmar, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Colmar Civil Hospitals, Colmar, France
Background/Purpose: Hyperuricemia (HU), a common metabolic abnormality, may result in development of gout, which is an inflammatory arthritic condition1,2. Patients (pts) with psoriasis (PsO)/psoriatic arthritis…
Abstract Number: 1789 • ACR Convergence 2022
Gout in Heart Failure Patients with Left Ventricular Assist Device Therapy in a Tertiary Academic Hospital
Aakriti Arora¹, Lakshmi Jayaram², TEFERA ESHETU³ and FLORINA CONSTANTINESCU³, ¹MedStar Washington Hospital Center, Georgetown University, Washington, DC, ²McGaw Medical Center, Northwestern University, Chicago, IL, ³MedStar Washington Hospital Center, Washington, DC
Background/Purpose: Gout is one of the most common inflammatory joint diseases and is a disabling complication in patients with heart failure. Patients with gout and…
Abstract Number: 1808 • ACR Convergence 2022
Assessing the Role of the NLRP3 Inflammasome in Driving Inflammation in Affected Joints of Patients with Inter-critical Gout
Swamy Venuturupalli¹, Ami Ben-artzi², Tasmia Amjad³, Amit Kumar⁴, Nikhil Davuluri³, Timothy Chu³, Umair Khan³, Diego Parra³, Natalie Fortune³ and Caroline Jefferies¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ³Attune Health, Beverly Hills, CA, ⁴Attune Health, Beverly Hils, CA
Background/Purpose: Percutaneous ultrasound-guided needle synovial biopsies can now be performed at the bedside. To date, no synovial biopsy studies have been conducted in gout patients.…
Abstract Number: 1828 • ACR Convergence 2022
Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
Rachael Flood¹, Colm Kirby¹, yousef Alammari², David Kane¹ and Ronan Mullan¹, ¹Tallaght University Hospital, Dublin, Ireland, ²Imam Mohammad Ibn Saud Islamic University, RIYADH, Ar Riyad, Saudi Arabia
Background/Purpose: Emerging evidence that joints of asymptomatic hyperuricaemic individuals contain monosodium urate (MSU) deposits and that alternative presentations of foot pain occur in hyperuricaemia suggests…
Abstract Number: 1068 • ACR Convergence 2022
Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype
Maria Herran¹, Brit Adler², Jamie Perin³, Walter Morales⁴, Mark Pimentel⁵ and Zsuzsanna McMahan⁶, ¹School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, ²Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ³John Hopkins University, Baltimore, MD, ⁴Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, ⁵Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles, CA, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: The gastrointestinal tract is commonly affected in systemic sclerosis (SSc). Prior studies have reported an association between higher levels of anti-vinculin antibodies and gastrointestinal…
Abstract Number: 1791 • ACR Convergence 2022
Point-of-Care Multi-Energy Photon-Counting CT for Earlier Non-Invasive Diagnosis of Gout and Calcium Pyrophosphate Deposition Disease
Fabio Becce¹, Anais Viry², Damien Racine², David Rotzinger¹, Tristan Pascart³, Georgios Filippou⁴, Jérôme Damet² and Lucia Gallego Manzano², ¹Lausanne University Hospital (CHUV), Lausanne, Switzerland, ²Institute of Radiation Physics, Lausanne, Switzerland, ³Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁴Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy
Background/Purpose: While the definitive diagnosis of gout and calcium pyrophosphate deposition disease (CPPD) is still based on the identification of characteristic crystals in synovial fluid…
Abstract Number: 1809 • ACR Convergence 2022
Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial
Keigo Hayashi¹, yuqing zhang², Hyon Choi³ and Kazuki Yoshida⁴, ¹Brigham and Women's Hospital, Okayama, Japan, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Low-dose colchicine has been demonstrated to reduce cardiovascular (CV) events in two recent large cardiovascular trials. Gout patients, for whom colchicine is a highly relevant…
Abstract Number: 1829 • ACR Convergence 2022
Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
Lindsay Helget¹, Anne Davis-Karim², James O'Dell¹, Ted Mikuls³, Jeff Newcomb¹, Maria Androsenko⁴, Mary Brophy⁴, Bryant England¹, Ryan Ferguson⁴, Michael Pillinger⁵, Tuhina Neogi⁶, Hongsheng Wu⁴ and Paul Palevsky⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Boston University School of Medicine, Boston, MA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone in the treatment of gout, which afflicts over 2 million individuals with chronic kidney disease (CKD) in…
Abstract Number: 1128 • ACR Convergence 2022
The Causal Association Between Osteoarthritis and Common Comorbidities: A Mendelian Randomisation Study
William Thompson¹, Subhashisa Swain², Sizheng Zhao³, Anne Kamps⁴, Carol Coupland⁵, Chang-Fu Kuo⁶, Michael Doherty⁵ and Weiya Zhang⁵, ¹University of Nottingham, Exeter, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵University of Nottingham, Nottingham, United Kingdom, ⁶Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: Osteoarthritis (OA) is the most common cause of joint pain and a major cause of disability. OA commonly associates with other conditions, such as…
Abstract Number: 1792 • ACR Convergence 2022
Contemporary Racial/Ethnic Disparities in Emergency Department Visits and Hospitalizations for Gout in the United States – 2019 Nationwide Analysis
Chio Yokose¹, natalie mccormick², na lu³, amit johi⁴, Lesley Jackson⁵, Minna Kohler⁶, Janeth Yinh², yuqing zhang⁷, John Hsu², kenneth saag⁵ and Hyon Choi⁸, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Arthritis Research Canada, Boston, MA, ⁴Regeneron, Boston, MA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁷Massachusetts General Hospital, Quincy, MA, ⁸MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout is a highly prevalent inflammatory arthritis with increasing global disease burden in recent years.1,2 A recent analysis3 of the Multiethnic Cohort Study reported…
Abstract Number: 1810 • ACR Convergence 2022
Frequency and Patterns of Opioid Use in the Management of Gout: A Population-Based Study
Tuhina Neogi¹, Martin Englund², Aleksandra Turkiewicz² and Ali Kiadaliri², ¹Boston University School of Medicine, Boston, MA, ²Lund University, Lund, Sweden
Background/Purpose: Treatment guidelines for management of gout do not recommend opioids. We evaluated the frequency of opioid prescriptions in those with gout compared with the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].